Exploratory analysis of disease progression and natural history of FTD Lead Investigator: Timothy Swan Institution : Biogen E-Mail : timothy.swan@biogen.com Proposal ID : 1410 Proposal Description: Collaborating with Flavia Nery O?Donnell, John O?Gorman, and Alexis Ang for analyses This dataset is being requested to support Biogen's Frontal Temporal Dementia (FTD) program research. There are several key aims of the research, with the expected values described below. (1) Estimation of disease progression: Improved understanding of longitudinal change and variability of functional, cognitive, behavioral, and biomarker measures, would allow identification of measures that are most sensitive to change and predictive of disease progression in the FTD population, thus informing the choice of key endpoints and inclusion/exclusion criteria in clinical trials for new FTD therapies. (2) Factors associated with disease progression, including demographic, medical, clinical measures, and biomarkers: Improved prediction of disease progression may help identify patient subgroups with a faster or more burdensome disease course, to support the value of and access to new FTD therapies. (3) Prevalence and incidence of comorbidities and use of prescription medications associated with medical events, or cognitive or behavioral symptoms, among FTD patients: Improved pharmacovigilance plan at time of marketing authorization submission regarding the expected (i.e., background) rates of adverse events Improved understanding of the medical characteristics of FTD patients outside of the clinical trial setting that may impact the benefit-risk profile of new FTD therapies (4) Characteristics of patients with FTD across different research cohorts: Compare the NACC FTD cohort, and subgroups thereof defined in terms of phenotyp